Suppr超能文献

相似文献

2
Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat.
J Immunol. 2012 Sep 1;189(5):2597-605. doi: 10.4049/jimmunol.1201272. Epub 2012 Jul 27.
5
Human neutrophil membrane-derived nanovesicles as a drug delivery platform for improved therapy of infectious diseases.
Acta Biomater. 2021 Mar 15;123:354-363. doi: 10.1016/j.actbio.2021.01.020. Epub 2021 Jan 18.
8
Rapid and sustained antidepressant effects of resolvin D1 and D2 in a chronic unpredictable stress model.
Behav Brain Res. 2017 Aug 14;332:233-236. doi: 10.1016/j.bbr.2017.06.010. Epub 2017 Jun 10.
9
D-series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization.
FASEB J. 2016 Dec;30(12):4192-4201. doi: 10.1096/fj.201600144RR. Epub 2016 Sep 12.

引用本文的文献

2
Lung Inflammation Resolution by RvD1 and RvD2 in a Receptor-Dependent Manner.
Pharmaceutics. 2023 May 18;15(5):1527. doi: 10.3390/pharmaceutics15051527.
3
Allosteric modulation of α1β3γ2 GABA receptors by farnesol through the neurosteroid sites.
Biophys J. 2023 Mar 7;122(5):849-867. doi: 10.1016/j.bpj.2023.01.032. Epub 2023 Jan 31.
5
Nanoparticles in the diagnosis and treatment of vascular aging and related diseases.
Signal Transduct Target Ther. 2022 Jul 11;7(1):231. doi: 10.1038/s41392-022-01082-z.
6
Resolvin D1-loaded nanoliposomes promote M2 macrophage polarization and are effective in the treatment of osteoarthritis.
Bioeng Transl Med. 2022 Mar 7;7(2):e10281. doi: 10.1002/btm2.10281. eCollection 2022 May.
7
Mechanistic Understanding from Molecular Dynamics in Pharmaceutical Research 2: Lipid Membrane in Drug Design.
Pharmaceuticals (Basel). 2021 Oct 19;14(10):1062. doi: 10.3390/ph14101062.
8
Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-Acting 2-Adrenergic Receptor Agonists.
Mol Pharmacol. 2021 Oct;100(4):406-427. doi: 10.1124/molpharm.121.000285. Epub 2021 Aug 1.
9
Human neutrophil membrane-derived nanovesicles as a drug delivery platform for improved therapy of infectious diseases.
Acta Biomater. 2021 Mar 15;123:354-363. doi: 10.1016/j.actbio.2021.01.020. Epub 2021 Jan 18.
10
Nanomedicine for Ischemic Stroke.
Int J Mol Sci. 2020 Oct 14;21(20):7600. doi: 10.3390/ijms21207600.

本文引用的文献

1
Generation, purification and engineering of extracellular vesicles and their biomedical applications.
Methods. 2020 May 1;177:114-125. doi: 10.1016/j.ymeth.2019.11.012. Epub 2019 Nov 30.
2
Resolvin D2 elevates cAMP to increase intracellular [Ca] and stimulate secretion from conjunctival goblet cells.
FASEB J. 2019 Jul;33(7):8468-8478. doi: 10.1096/fj.201802467R. Epub 2019 Apr 23.
3
pH-Responsive Nanoparticles Targeted to Lungs for Improved Therapy of Acute Lung Inflammation/Injury.
ACS Appl Mater Interfaces. 2019 May 8;11(18):16380-16390. doi: 10.1021/acsami.9b04051. Epub 2019 Apr 24.
4
Integrin activation by the lipid molecule 25-hydroxycholesterol induces a proinflammatory response.
Nat Commun. 2019 Apr 1;10(1):1482. doi: 10.1038/s41467-019-09453-x.
6
Neutrophil Membrane-Derived Nanovesicles Alleviate Inflammation To Protect Mouse Brain Injury from Ischemic Stroke.
ACS Nano. 2019 Feb 26;13(2):1272-1283. doi: 10.1021/acsnano.8b06572. Epub 2019 Jan 28.
7
Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions.
Cell Chem Biol. 2019 Feb 21;26(2):244-254.e4. doi: 10.1016/j.chembiol.2018.10.023. Epub 2018 Dec 13.
8
Lipoxin and Resolvin Receptors Transducing the Resolution of Inflammation in Cardiovascular Disease.
Front Pharmacol. 2018 Nov 14;9:1273. doi: 10.3389/fphar.2018.01273. eCollection 2018.
9
Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management.
Adv Mater. 2018 Oct;30(43):e1803618. doi: 10.1002/adma.201803618. Epub 2018 Sep 11.
10
Pro-resolving lipid mediators in vascular disease.
J Clin Invest. 2018 Aug 31;128(9):3727-3735. doi: 10.1172/JCI97947.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验